전립선비대증 환자에서 항콜린제 추가 투여 시 순응도에 영향을 미치는 요인

Purpose: Anticholinergic agents are effective in relieving overactive bladder symptoms and historically has been contraindicated in benign prostatic hyperplaisa (BPH) patients because of concerns for developing acute urinary retention. Recently, however, treatment for men with predominant storage symptoms is combined with an antichoilnergic agents. We evaluated the efficacy, discontinuation rate, adverse events and clinical parameters of α-blockers and/or 5α-reductase inhibitors treatment combined with anticholinergic agents in patients with lower urinary tract symptoms (LUTS). Materials and Methods: 137 patients with BPH, who had treated with α-blockers and/or 5α-reductase inhibitors combined with anticholinergic agents at our department from January 2003 to November 2008, were retrospectively studied. In 92 patients, anticholinergic agents continued to be administered (group I) and in 45 patients, ceased to be given (group II). The efficacy and adverse events of anticholinergics treatment were estimated. The International Prostate Symptom Score (IPSS), serum prostate specific antigen (PSA) level, prostate volume, maximum urinary flow rate and residual urine volume before administration of anticholinergics were evaluated. The change in maximum urinary flow rate and residual urine volume and the presence of acute urinary retention after giving anticholinergics were compared. Results: There was no significant difference comparing age, IPSS, serum PSA levels, prostate volum, maximum urinary flow rate and residual urine volume except IPSS storage subscore between the two groups. In group I, there was no significant change in maximum urinary flow rate and residual urine volume after administering anticholinergics. IPSS storage subscore were more significant in group I (9.0±3.4 vs 7.4±3.4, p